Preventive effects of ginseng against atherosclerosis and subsequent ischemic stroke: A randomized controlled trial (PEGASUS trial).

"Declaration of competing interest The authors declare no conflicts of interest."

"Funding This study was supported by Korean Ginseng Cooperation (No. KGC2016-26)."

"This was a 12-month, randomized, double-blind, placebo-controlled, and single center trial. A study drug was a 500-mg KRG extract tablet manufactured by Korean Ginseng Corporation, and A placebo was fabricated in identical appearance of the KRG extract tablet []. Each subject was randomized in a 1:1 ratio to the ginseng or placebo group according to random permuted blocks. All investigators, participants, and their caregivers were blinded to group assignment throughout the study period. The study protocol conformed to Good Clinical Practice guidelines and the Declaration of Helsinki, and was approved by the institutional review board of our institution (No. 2015-1350). This trial was registered at ClinicalTrials.gov (No. NCT02796664) ()."